News Conference News AHA 2025 Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN Michael O'Riordan November 08, 2025
News Conference News AHA 2024 Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F Michael O'Riordan November 16, 2024
News Conference News AHA 2024 One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024 Shelley Wood November 14, 2024
News Conference News AHA 2023 NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear L.A. McKeown November 12, 2023
News Conference News AHA 2022 RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl Todd Neale November 10, 2022
News Conference News AHA 2021 Racial/Ethnic Disparities in AF Care Persist Despite Dual VA, Medicare Coverage Todd Neale November 19, 2021
News Conference News AHA 2021 No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials Todd Neale November 15, 2021
News Conference News AHA 2019 Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS Todd Neale November 20, 2019
News Conference News AHA 2019 Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR Todd Neale November 17, 2019
News Conference News AHA 2017 Angiography, Revascularization Safe in Acute MI Patients Taking OACs for Atrial Fibrillation Michael O'Riordan November 13, 2017
News Conference News AHA 2016 Dabigatran Reversal Agent’s Safety, Efficacy Affirmed With Updated Study Results Todd Neale November 15, 2016